TICKERNERD
Menu
ESTAESTAHealthcare · Medical Devices

ESTA Stock Forecast: Establishment Labs Holdings, Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$58
−0.98% on the day

The 9 Wall Street analysts covering Establishment Labs Holdings, Inc. hold a median 12-month price target of $105 — +81.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 74 of 100 as at 14 Oct 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$1.7B
Ticker Nerd rank
74 / 100
Median analyst target
$105
Analysts covering
9
Revenue$67.5M+31.7% y/y
Operating income−$4.3M
Net income−$11.7M
Free cash flow−$20.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.4%
1M
−19.5%
YTD
−20.6%
1Y
+30.4%
From 52W high
−39.5%
From 52W low
+30.4%
$44
$96
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ESTA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Establishment Labs Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
74 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
94
Quality
81
Momentum
76
Revisions
71
Volatility
67
Value
54
Accruals
50
Size
37
Issuance
18

Growth (94): Sales and profits are climbing, and climbing faster than before.

Issuance (18): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ESTA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ESTA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$40$60$80$100$120Jan 26Apr 26Jul 26Oct 26ESTAHigh $117Median $105Low $92

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
9 Buy0 Hold0 Sell
Low $92Median $105High $117

The green dot is the last close — the median target sits +81.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
1 Sept 2026BTIGReiteratesBuy$103
13 Aug 2026CitigroupUpgradeBuy$92
13 Aug 2026CitigroupUpgradeBuy—
7 Aug 2026JP MorganMaintainsOverweight$84 → $95
7 Aug 2026JP MorganMaintainsOverweight—
6 Aug 2026BTIGMaintainsBuy—
6 Aug 2026BTIGMaintainsBuy$96 → $103
6 Aug 2026NeedhamMaintainsBuy—
6 Aug 2026NeedhamMaintainsBuy$86 → $95
3 Aug 2026TD CowenMaintainsBuy—
3 Aug 2026TD CowenMaintainsBuy$95 → $117
15 July 2026MizuhoMaintainsOutperform$100 → $105
15 July 2026MizuhoMaintainsOutperform—
8 July 2026CitigroupMaintainsNeutral$76 → $92
8 July 2026CitigroupMaintainsNeutral—
7 May 2026BTIGMaintainsBuy—
29 Apr 2026BTIGReiteratesBuy—
11 Mar 2026CitigroupMaintainsNeutral—
26 Feb 2026Canaccord GenuityMaintainsBuy—
25 Feb 2026MizuhoMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ESTA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ESTA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, Establishment Labs Holdings, Inc. returned +30.4% against +17.5% for the S&P 500, dividends included.

ESTA vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160180200220Jan 26Apr 26Jul 26Oct 26ESTAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ESTA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Establishment Labs Holdings, Inc. (ESTA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−33.9×

Cheaper than 98% of US stocks

Price / sales
7.1×

Cheaper than 18% of US stocks

Price / book
80.6×

Cheaper than 2% of US stocks

EV / EBITDA
−225.9×

Cheaper than 98% of US stocks

Growth & margins
Revenue growth (YoY)
31.7%

Higher than 78% of US stocks

Earnings growth (YoY)
31.7%

Higher than 66% of US stocks

Gross margin
70.6%

Higher than 83% of US stocks

Operating margin
−6.4%

Higher than 26% of US stocks

Net margin
−15.8%

Higher than 17% of US stocks

Returns & dividend
Return on equity
−175.3%

Higher than 8% of US stocks

Return on assets
−3.4%

Higher than 34% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Establishment Labs Holdings, Inc. (ESTA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Establishment Labs Holdings, Inc. has a market value of $1.7B and an enterprise value of $2.0B.

  • Revenue in the twelve months to 30 June 2026: $245.8M. The latest quarter grew 31.7% year on year.

  • Net income over the same four quarters: −$38.9M, a −15.8% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.31.

  • Free cash flow in the twelve months to 30 June 2026: −$41.6M.

  • Shares outstanding: 29.8M.

  • Trailing P/E: −33.9×; forward P/E: 974.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Establishment Labs Holdings, Inc. employs 1,004 people — $245K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Oct 2026

Data provided by Twelve Data

Peers

ESTA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
ESTAEstablishment Labs Holdings, Inc.$1.7B
74
ALMRAlamar Biosciences, Inc. (California)$1.7B
4
NVCRNovoCure Ltd.$1.6B
96
ATECAlphatec Holdings, Inc.$1.6B
74
INSPInspire Medical Systems, Inc.$1.9B
87
CNMDCONMED Corp.$1.4B
95
AXGNAxogen, Inc.$2.1B
80

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Establishment Labs Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ESTA news & analysis

Establishment Labs® Receives FDA Approval for Additional Sizes of Motiva Implants®

Business Wire · 5 Oct 2026positive

Establishment Labs Holdings Inc. announced that the U.S. FDA approved an expanded range of Motiva SmoothSilk Round and Motiva SmoothSilk Ergonomix breast implants, adding 28 new sizes to its U.S. portfolio.

Why it matters — An expanded FDA-approved size range for Motiva implants broadens Establishment Labs' product offering in the U.S. breast aesthetics and reconstruction market.

Establishment Labs® Highlights New Breast Tissue Preservation Data and Announces Minimally Invasive Product Extensions at the 11th World Symposium on Ergonomic Implants

Business Wire · 21 Sept 2026positive

Establishment Labs announced the presentation of new clinical and scientific data supporting Breast Tissue Preservation and its Minimally Invasive Platform at the 11th World Symposium on Ergonomic Implants. The company also announced product line extensions for Mia and Preservé with new sizes and supporting tools.

Why it matters — A watcher of ESTA would care because the company is highlighting new clinical data and expanding its Mia and Preservé product lines, which could support its position in breast aesthetics and reconstruction.

Establishment Labs: Procedure Economics Strengthens The Bull Case

Seeking Alpha · 9 Sept 2026positive

Establishment Labs reported Q2 2026 results showing 31.7% revenue growth, gross margin expansion to 70.6%, and U.S. sales accounting for 89% of total growth, driven by FDA approval and U.S. market entry with its Preservé procedure-based offering. The company notes Preservé delivers more than twice the revenue per procedure versus traditional augmentation, though long-term success depends on repeat utilization and durable economics.

Why it matters — The report highlights how Establishment Labs' FDA approval and Preservé procedure economics are driving high-margin growth in the U.S., a key factor in assessing the company's bull case and long-term revenue durability.

Baron Discovery Fund Q2 2026 Portfolio Activity

Seeking Alpha · 28 Aug 2026neutral

Baron Discovery Fund reported its Q2 2026 portfolio activity, discussing growth prospects for its holdings, including Samsara, Shake Shack, and a new position in Rubrik. The fund commentary does not mention Establishment Labs Holdings, Inc. (ESTA).

Why it matters — ESTA watchers would note that this fund update contains no commentary on the company, so it offers no direct insight into the firm's ESTA position.

Establishment Labs Holdings Inc. (ESTA) Q2 2026 Earnings Call Transcript

Seeking Alpha · 6 Aug 2026neutral

Establishment Labs Holdings Inc. (ESTA) released the transcript of its Q2 2026 earnings call, as published on Seeking Alpha. The document covers the company's second-quarter 2026 financial results and management discussion.

Why it matters — A transcript of the Q2 2026 earnings call gives ESTA watchers direct insight into the company's latest quarterly performance and management commentary.

FAQ

Frequently asked questions about ESTA stock

What is the ESTA stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Establishment Labs Holdings, Inc. have a median 12-month price target of $105, with estimates ranging from $92 to $117. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ESTA stock a buy right now?

Of the 9 analysts covering Establishment Labs Holdings, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Establishment Labs Holdings, Inc. 74 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ESTA?

As at 14 Oct 2026, Establishment Labs Holdings, Inc. ranks 74 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (94 of 100).

Will ESTA stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +81.4% from the last close, and Ticker Nerd's factor model ranks Establishment Labs Holdings, Inc. 74 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ESTA stock forecast for 2030?

No analyst covering Establishment Labs Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ESTA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $92 to $117 over the next 12 months.

How has ESTA stock performed over the past year?

Establishment Labs Holdings, Inc. returned +30.4% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Establishment Labs Holdings, Inc. do?

Establishment Labs Holdings Inc. is a medical technology company focused on breast aesthetics and reconstructive plastic surgery.

What is the latest news on ESTA?

The most recent item we track (Business Wire, 5 Oct 2026): "Establishment Labs® Receives FDA Approval for Additional Sizes of Motiva Implants®". Establishment Labs Holdings Inc. announced that the U.S. FDA approved an expanded range of Motiva SmoothSilk Round and Motiva SmoothSilk Ergonomix breast implants, adding 28 new sizes to its U.S. portfolio.

Company

About Establishment Labs Holdings, Inc.

Establishment Labs Holdings Inc. is a medical technology company focused on breast aesthetics and reconstructive plastic surgery. Its core portfolio includes silicone gel-filled breast implants under the Motiva Implants brand, along with breast tissue expanders and related surgical technologies used in augmentation and reconstruction procedures. The company serves physicians, hospitals, and clinics through a combination of direct sales and distributor networks, supporting commercial activity across Europe, the Middle East, Africa, Latin America, Asia, and the United States. Establishment Labs Holdings Inc. also develops products and platforms designed to support surgical planning and procedural workflows in aesthetic and reconstructive care. Headquartered in Austin, Texas, the company plays a specialized role in the global medical device market by supplying devices centered on women’s health, breast reconstruction, and aesthetic surgery.

CEO Mr. Fillipo Peter Caldini · 1,004 employees · United States · https://www.establishmentlabs.com